Try our beta test site

Testing the Re-Engineered Hospital Discharge

This study has been completed.
Information provided by:
Boston University Identifier:
First received: November 10, 2005
Last updated: January 14, 2016
Last verified: April 2009
Results First Received: February 10, 2009  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Single Blind (Outcomes Assessor);   Primary Purpose: Prevention
Condition: All
Intervention: Behavioral: Re-Engineered Discharge

  Participant Flow

  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
Re-engineered Hospital Discharge Participants received the "Re-Engineered Hospital Discharge", a set of 11 discrete, mutually reinforcing components provided by a Discharge Advocate and re-enforced by a telephone call 2-4 days after discharge by a clinical pharmacist.
Standard Hospital Discharge Participants received the routine, standard hospital discharge.
Total Total of all reporting groups

Baseline Measures
   Re-engineered Hospital Discharge   Standard Hospital Discharge   Total 
Overall Participants Analyzed 
[Units: Participants]
 373   376   749 
[Units: Participants]
<=18 years   0   0   0 
Between 18 and 65 years   312   314   626 
>=65 years   61   62   123 
[Units: Years]
Mean (Standard Deviation)
 50.1  (15.1)   49.6  (15.3)   49.9  (15.2) 
[Units: Participants]
Female   178   199   377 
Male   195   177   372 
Region of Enrollment 
[Units: Participants]
United States   373   376   749 

  Outcome Measures

1.  Primary:   Total Number of Rehospitalizations (Emergency Department Visits Plus Hospital Admissions) in the 30 Days After Discharge.   [ Time Frame: 30 days after discharge ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

  More Information